Last reviewed · How we verify

NCT03826329: 2nd ACDF

Risk Factors of Second Surgery for Adjacent Segment Disease Following Anterior Cervical Discectomy and Fusion

Completed Last updated 1 February 2019
What this trial tests

trial testing observational study in Spinal Fusion in 5,565 participants. Completed in 30 November 2018.

Timeline
11 September 2018
Primary endpoint
30 November 2018
30 November 2018

Quick facts

Lead sponsorTaipei Veterans General Hospital, Taiwan
StatusCompleted
Study typeOBSERVATIONAL
Enrollment5,565
Start date11 September 2018
Primary completion30 November 2018
Estimated completion30 November 2018
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Taipei Veterans General Hospital, Taiwan

Who can join

Eligibility, any sex, with Spinal Fusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Although the incidence of second surgery for adjacent segment disease (ASD) after anterior cervical discectomy and fusion (ACDF) has been reported, its risk factors remain elusive. Few studies have had a sufficiently large number of patients, long follow-up time, and high follow-up rate for investigation. To identify non-surgical risk factors of second surgery for ASD following ACDF, the study used a national cohort with comprehensive follow-up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of observational study

Trials testing the same drug.

Other recruiting trials for Spinal Fusion

Currently open trials in the same condition.

Other Taipei Veterans General Hospital, Taiwan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03826329.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing